BOOK BY FRIDAY, DECEMBER 7 AND SAVE $400

March 19-21, 2019 | Boston

www.ici-io.com

ICI-IO COMBINATIONS SUMMIT 2019

Revolutionizing Combination Selection Processes to Optimize Response Rates, Effectiveness & Safety

A Case Study Based Look at IO Combinations in the Context of the Cancer Immunity Cycle



Expert Speakers Including:

Stephen Doberstein
Senior Vice President Research & Development and Chief of Research & Development
NEKTAR Therapeutics

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Raphael Clynes
Vice President of Translational Biology
Xencor

Patrick Holder
Protein Chemistry Scientist
Genentech

Jochem Gokelmeijer
Associate Director
Bristol-Myers Squibb

Catherine Sabatos-Peyton
Director
Novartis

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Mithun Khattar
Scientist & Immuno-Oncology Lead
Takeda

Paul Moore
Vice President - Cell Biology & Immunology
MacroGenics

Partners: MITRA BIOTECH™ applied biomath® Personalis® IMMUDEX

Tel: +1 617 455 4188 **Mail:** info@hansonwade.com
Immune Checkpoint Inhibitors @ici_checkpoint

hansonwade

Increasing Effectiveness and Safety of IO Combinations

This industry-led meeting will focus on how **checkpoint combinations can impact every stage of the cancer immunity cycle;** enhancing patient outcomes.

The unique format of the agenda offers a complete perspective of the effects of adaptive and innate immune components on combination success. Appreciate insights on the latest data on how drug developers are targeting of immune checkpoints, myeloid cells, cytokines, stromal cells, STING and kinase pathways such as Wnt & PI3K.

Breaking down these case-studies gives the opportunity to take un-pick specific preclinical, translational and clinical challenges. Bringing forward new ideas and concepts that you can build into your combination rationale. Stop taking shots in the dark, and start formulating calculated, precise studies that will yield results and true clinical value.

Hear What Previous Attendees Have To Say

"Great meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy"

Genentech

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics"

AstraZeneca

"Great opportunity for discussions between large pharma, small start ups, academia and regulatory authorities"

Merck

An Unparalleled Depth of Insights

1. **Improve your combination rationale** with a greater mechanistic understanding of the cancer immunity cycle and how combinations work within it

2. Learn how Nektar Therapeutics supercharge the tumor microenvironment to **optimize the effectiveness of checkpoint modulators** through the use of cytokines



3. Hear how Jounce Therapeutics reverse translated their ICOS - containing combination when it didn't perform as expected to **better inform future decision making**

4. Take apart the current approaches to target identification from biological and protein chemistry perspectives to **find a faster, more efficient path to preclinical testing** with a discussion between panelists from Genentech, Novartis and FusionBio

5. Predict and plan for future roadblocks to development through our interactive workshops on **preclinical development of IO combinations** and **maximizing the anti-tumor capability of the innate immune system**

YOUR EXPERT SPEAKERS

John M. Burke
Co-Founder, President, and Chief Executive Officer
Applied Biomath

Amy-Jo Casbon
Immunotherapy & Oncology Scientist
Amgen Inc.

Raphael Clynes
Vice President of Translational Biology
Xencor

Viviana Cremasco
Investigator
Novartis

Stephen Doberstein
Senior Vice President Research & Development and Chief of Research & Development
NEKTAR Therapeutics

Cedric Dos Santos
Prinicpal Scientist Heme, Oncology, Clinical Biomarkers & Therapeutic Areas Lead
Amgen Inc.

Hans Van Eenemann
Executive Vice President Antibody Research and Site Head
Aduro Biotech

Shanthi Ganesh
Associate Director
Dicerna

Personalis
Speaker TBC

Jochem Gokelmeijer
Associate Director
Bristol-Myers Squibb

Jeremy Graff
Chief Scientific Officer
Biothera

Patrick Holder
Protein Chemistry Scientist
Genentech

Mithun Khattar
Scientist & Immuno-Oncology Lead
Takeda

Paul Moore
Vice President - Cell Biology & Immunology
MacroGenics

Bruno Osterwalder
BO Consulting

Mark Paris
Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Weiyi Peng
Assistant Professor
MD Anderson Cancer Centre

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Catherine Sabatos-Peyton
Director
Novartis

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Wim Van Schooten
Chief Scientific Officer
TeneoBio

Eva Vanamee
Co-Founder
Fusion Bio

Bei Wang
Staff Scientist
Regeneron

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Sarah McWhirter
Director - Sting Program
Aduro Biotech

PRE-CONFERENCE WORKSHOP DAY
MARCH 19, 2019

Pre-Clinical Development Challenges in Checkpoint Modulators and IO Combinations

9:00am - 12:00pm

The path to clinical success begins in the lab. We have seen a lot of molecules struggled through clinical phases due to a lack of pre-clinical understanding.

This workshop will give you the practical skills and insight to help you make informed decisions at the preclinical phase, leading you to more robust and reliable results at the trial stage. Through case studies and group discussions, this interactive session will dive into the following areas, which prime your preclinical understanding prior to the main conference.

Topics that are being covered include:

- A breakdown of the models that are currently available, their relative translatability and where they can be implemented best for both ICIs and IO combinations
- An analysis of the key challenges that are being faced at the preclinical stage and the key developments that will enable us to overcome them
- Look at how you can build a robust scientific rationale at the preclinical stage to drive greater success at the clinical phase

Mithun Khattar
Scientist & Immuno-Oncology Lead
Takeda

"Excellent meeting. Great opportunity for discussions between large pharma, small start ups, academia and regulatory authorities"
Merck



CONFERENCE DAY ONE
MARCH 20, 2019

	8.30	**Chair's Opening Remarks**
Mark Yore Manager of Corporate Development **Jounce Therapeutics**	**8.40**	**Navigating the complex ICI-IO landscape – Recent updates and Future Challenges** • As the number of CPI-IO trials continue to grow at unprecedented rates, understanding the complex nature of this landscape is critical for clinical and commercial success • During the presentation I will discuss the landscape as it stands today, how it's evolving, and key challenges that face ICI-containing IO-combinations in the future
Paul Rennert President and Chief Scientific Officer **Aleta Biotherapeutics**	**9.10**	**Establishing a New Set of Biological Goals for Checkpoint Inhibitors and IO Combinations** • Look at the current standards that are in place for ICIs and IO combinations • Set new goals that scientists must strive to achieve in order to set a new standard of care
John M. Burke Co-Founder, President, and Chief Executive Officer **Applied Biomath**	**9.40**	**Model Aided Drug Invention Case Study: GITR-Mediated T Cell dynamics in Mouse Tumor Micro Environment** • Model Aided Drug Invention (MADI) is a mechanistic mathematical modeling approach used to help reduce late stage attrition rates, help accelerate the development of premier (or best-in-class) therapeutics and identify potential R&D hurdles • In this collaboration, a MADI approach was used to develop and analyze a systems pharmacology model of an anti-GITR (Glucocorticoid-Induced TNFR-Related protein) agonist antibody to predict Treg and Teff dynamics in the tumor microenvironment in two syngeneic mouse models following administration of anti-GITR agonist antibody • The model adequately described the time profiles of intratumoral Treg and Teff, captured Teff immune checkpoint, Treg depletion by ADCP, and Teff proliferation and differentiation into cytotoxic T lymphocytes (CTLs). The model also provided a quantitative understanding of the trade-off between maximizing Treg depletion vs. Teff agonism
	10.10	**Speed Networking & Morning Refreshments**

Broadening Understanding of the Biological Effects of Checkpoint Inhibitors

Stephen Doberstein Senior Vice President Research & Development and Chief of Research & Development **NEKTAR Therapeutics**	**11.30**	**Supercharging the Tumor Microenvironment: Lessons from NKTR-214 and Opdivo** • The idea of combining the immune modulating properties of checkpoint inhibitors and the immune stimulating function of engineered cytokines is conceptually powerful • Cytokine engineering can alternative cytokines to be more powerful medicines, while controlling adverse events • The combination of NKTR-214 with opdivo has demonstrated powerful anti tumor effects and profoundly alters the tumor microenvironment, increasing effector T-cell counts, increasing PD-1 expression on tumor T-cells, and converting PD-L1 negative tumors to positive, while maintaining a more tolerable AE profile than traditional cytokine therapies
Mark Paris Director, Translational Applications Biopharma Business Development **Mitra Biotech Inc.**	**12.00**	**A Clinically-Predictive Ex-Vivo Tumor Modelling Platform for Drug Discovery and Development** • Mitra Biotech has developed and clinically validated a fully human ex-vivo tumor platform technology (CANscript™) • CANscript ™ uses patient material (tumor, autologous ligands and PBMCs) to explore the mechanism of action and predict efficacy for clinically-directed compounds in a modality agnostic way using phenotypic readouts • This talk will explore how we use CANscript to measure the effect of checkpoint inhibitor monotherapy or combination to deepen our understanding of response and resistance

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

12.30 Lessons Learned from a Clinical Trial Targeting ICOS

- JTX-2011, an ICOS agonist, was evaluated as monotherapy and in combination with nivolumab in the ICONIC trial
- Responses and tumor reductions observed with monotherapy and combination were associated with a mechanism related pharmacodynamic biomarker
- Reverse translational analyses enabled by biomarkers have redirected JTX-2011 clinical development strategy

13.00 Lunch

Discovery

Enhancing Therapy Efficacy at the Preclinical Level

14.00 RNAi-mediated Inhibition of β-Catenin Increases Responses to Multiple Immunotherapy Regimens Across a Spectrum of Preclinical Tumor Models

- A systemically-administered RNAi drug product targeting β-catenin increases APCs and cytotoxic T-cells in the TME, and promotes synergistic efficacy in combination with immunotherapy in multiple preclinical models
- Identification of a novel mechanism by which Wnt/β-catenin signaling promotes resistance to immunotherapy
- Strategies to rationally design RNAi-containing drug combinations to increase the response rates to checkpoint blockade and IDO inhibition

Shanthi Ganesh, Associate Director – Oncology, **Dicerna**

14.30 Delineating Myeloid Cell Subsets and Their Role in Response to Cancer Immunotherapy

- Myeloid cell subsets associated with immune suppression and immune activation in cancer
- Combination therapies reveal new insights into the pro- and anti-tumor contribution of myeloid cells in cancer
- Emerging novel strategies for targeting myeloid cells to enhance cancer immunotherapy

Amy-Jo Casbon, Scientist – Oncology Research, **Amgen**

15.00 Bispecific and Biparatopic Human Heavy Chain Antibodies in Immune Oncology

- Discuss different formats of T cell engaging bispecific antibodies
- Explore biparatopic heavy chain antibodies against CD38

Wim Van Schooten, Chief Scientific Officer, **TeneoBio**

Translational

Overcoming Resistance & Personalizing Combination Therapies

14.00 Targeting the PI3K Pathway to Overcome Immune Resistance

- Discuss how tumor intrinsic signaling pathways modulate T cell-mediated antitumor immune responses.
- Identification of the mechanism by which oncogenic activation of the PI3K pathway promotes immune resistance
- Development of therapeutic strategies to improve the efficacy of cancer immunotherapy by combining with PI3K inhibition

Weiyi Peng, Assistant Professor, **MD Anderson Cancer Centre**

14.30 Discuss Our Innovative Platform and Core Technology Designed to Overcome Key Challenges in NGS from Poor Sample Quality and Quantity to Sequencing Gaps

- Introduce Personalis platform for neoantigen identification and biomarker discovery
- Enable comprehensive characterization of tumor immunogenomics including neoantigens, the tumor microenvironment, HLA, immunomodulators and mechanisms of tumor escape

Speaker TBC , Personalis

15.00 BiTE® in Hematologic Malignancies: a Road to a Cure?

- Review Blincyto® Biomarker data for R/R B-ALL patients with an emphasis on predictive and/or prognostic biomarkers, pharmacodynamic, mechanism of action and drug resistance mechanisms post treatment.
- Review biomarkers data for other Hem/Onc BiTE® molecules currently in Phase 1

Cedric Dos Santos, Principal Scientist - Heme, Oncology, Clinical Biomarkers & Therapeutic Areas Lead, **Amgen**

15.30 Afternoon Refreshments

Stages 1 – 3: Improving Cancer Antigen Presentation,Driving Stronger Priming and Immune Activation

Sarah McWhirter
Director - Sting Program
Aduro Biotech

16.00 STING Pathway Activation Enhances Checkpoint Blockade to Elicit an Anti-Tumor CD8+ T Cell Response in Preclinical Models

- Describe the rationale for targeting STING within the tumor microenvironment and the mechanism of optimal STING-induced anti-tumor CD8+ T cell immunity
- Highlight how STING activation enhances the therapeutic effect of checkpoint inhibition
- Explore the immune correlates associated with the combination of STING agonist-based immunotherapy and checkpoint inhibition

Bei Wang
Staff Scientist
Regeneron

16.30 T Cell Dysfunction and Combination Immunotherapy

- Single-cell analysis of tumor-infiltrating lymphocytes to probe the mechanisms for combination immunotherapy
- PD1/GITR combination immunotherapy led to a synergistic increase in tumor antigen–specific memory precursor effector T cells dependent on availability of the CD226 costimulatory pathway

17.00 Chair's Closing Remarks

CONFERENCE DAY TWO
MARCH 21, 2019

8.30 Chair's Opening Remarks

Jeremy Graff
Chief Scientific Officer
Biothera

8.40 Re-Training Innate Immunity: Combining the Novel Beta Glucan, Imprime PGG, with Checkpoint Inhibitors to Drive a Robust, Coordinated Anti-Cancer Immune Response

- Imprime PGG binds directly to cells of the innate immune system driving innate immune cell-mediated tumor killing, re-orienting macrophage polarization and enhancing antigen presentation capacity
- Imprime PGG thereby stimulates T cell-mediated immunity
- Imprime PGG mechanistically complements immune checkpoint inhibitor therapy to trigger a robust anti-cancer immune response

Raphael Clynes
Vice President of Translational Biology
Xencor

9.10 T Cell Engagers, Checkpoints and Cytokines to Broaden Immune Responses to Cancer

- IO therapy is limited by poor immune recognition, multiple checkpoints and insufficient T cell infiltration
- Xencor's pipeline is focused on overcoming these obstacles to broaden the reach of IO therapy
- CD3 bispecifics overcomes limited immune recognition by directly activating T cells by targeting common hematologic and solid tumor specific targets (CD20, CD123, SSTR2). Clinical trials and next gen approaches will be discussed
- Bispecific checkpoints clinical trials have been initiated at Xencor (DUET studies) targeting PD1, CTLA4, ICOS and LAG3. Rationale, preclinical antitumor activity and clinical plans/updates will be discussed
- Rationally designed T cell cytokines (IL-15 and others) with T cell targeting and long acting pharmacodynamic preclinical activity will be discussed that potently enhance intratumoral T cell infiltration

Patrick Holder
Protein Chemistry Scientist
Genentech

Catherine Sabatos-Peyton
Director
Amgen

Eva Vanamee
Co-Founder
FusionBio

9.40 Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

- Hear the perspectives from both biological and protein chemistry sides of the discussion
- Hone in on the key areas where each function can support one another in their shared goal of accelerating more clinical relevant IO drugs
- Look at the future targets for ICIs and IO combination therapies and assess their true value

10.30 Morning Refreshments

Discovery

Preclinical Testing and Tumor Modelling

11.00 Pre-Clinical Modeling of Immune Responses to Cancer: From Bench-Side to Clinical Outcomes

- Translatability of pre-clinical murine models in immuno-oncology.
- Pre-clinical models for investigating combination therapies.
- Fundamental differences in the immune system and tumor microenvironments of mice and humans

Mithun Khattar, Scientist & Immuno-Oncology Lead, **Takeda**

Translational

Clinical Biomarkers, Immunogenicity and Toxicity

11.00 Understanding Immune-Related Toxicities in the Era of Combination Immunotherapies

- Patterns of immune-related toxicities
- Factors that determine toxicities
- Comprehensive program to manage and prevent immune-toxicities

Osama Rahma, Assistant Professor, **Dana Faber**

11.30 Stromal-Imposed Immunosuppresion in the Era of Checkpoint Blockade

- Mesenchymal stromal cells impinge on anti-tumor immunity
- We still lack a full understanding of the cellular and molecular mechanisms by which stromal-imposed immunosuppression is exerted
- We have identified a discrete population of FAP+ stromal cells in immune-excluded breast cancers with potent immunomodulatory potentia

Viviana Cremasco, Investigator, **Novartis**

11.30 Immunogenicity of I-O Therapeutics: The Good and The Bad

- I-O therapeutic depended on manipulating immune checkpoints, one consequence of this is an a decreased tolerance including the therapeutic
- Is it possible that the MOA of I-O therapeutics contribute to immunogenicity to these therapeutics
- Are I-O combination therapies increasing immunogenicity and are there strategies to screen for this preclinical
- Strategies to mitigate immunogenicity to I-O therapeutics

Jochem Gokemeijer, Associate Director, **Bristol-Myers Squibb**

12.00 Panel Discussion: Reviewing the Future Challenges in Tumor Modeling for IO Combinations

- Review the current models and preclinical tools that are available and assess their true value in getting the results that predicate clinical successes and failures
- Identify the weak spots in current development strategies and discuss how these can be fixed

Mithun Khattar, Scientist & Immuno-Oncology Lead, **Takeda**

Viviana Cremasco, Investigator, **Novartis**

12.00 Panel Discussion: What Are the Solutions to The These Immunogenicity Challenges

- Consider a framework by which the effects of specific IO combos can be predicted, based on what was learnt in the talks prior
- Discuss trends that were seen between the previous presentations to solve their respective challenges
- Look at combining the capabilities of pharma and academia to solve these problems

Osama Rahma, Assistant Professor, **Dana Faber**

Jochem Gokelmeier, Associate Director, **Bristol-Myers Squibb**

12.45 Lunch

Stages 4 – 7: Trafficking and Infiltration of Immune Cells, Improving the Effectiveness Cell Destruction Mechanisms

Hans Van Eenemann
Executive Vice President Antibody Research and Site Head
Aduro Biotech

13.45 Targeting the Innate CD47-SIRPα Checkpoint Using Pan-Allele SIRPα Blocking Antibodies

- Unique pan-allele SIRPα blocking antibody
- SIRPα blocking differentiates from CD47 targeting
- SIRPα blocking enhances PD-1/PDL1 blocking in vivo

Paul Moore
Vice President
Macrogenics

14.15 PD-1-Based Bispecific Antibody Therapies

- Analyzing anti-drug-antibody (ADA) responses and the integrity of your bispecific format is of paramount importance in the preclinical and clinical development of any bispecific antibody.
- The selection of the right bioanalytical tools is a key consideration of this process

Bruno Osterwalder
Founder
B.O. Consulting

Jeremy Graff
Chief Scientific Officer
Biothera

14.45 Panel Discussion – How Can We Sort Through the Huge Number of Trials That are Currently Active?

- Should we pay more attention to the successes, or the failures?
- Have we made progress on developing preclinical rationales for immune-oncological combinations which will be more predictive in the clinic and allow earlier prioritization?
- What clinical data and results in early clinical development allow at the earliest point to decide to discontinue a combination?

15.15 Chair's Closing Remarks

PARTNER

Seize this opportunity to engage and network with the experts pioneering the immuno-oncology field

The potential of immuno-oncology combinations is clear, but in order for this potential to be realized, lessons and key insights from the companies who are directly involved in cutting edge development work must be shared and disseminated. The technical and specific focus of the ICI – IO Combinations means it is an unparalleled opportunity to engage in meaningful discussion with a focused group of experts working in the field. We are still seeking partners that will add value to the community and who can fast-track IO combination development.

Interactive sessions built into the main agenda provide extensive opportunities for you to align your services and hear industry feedback

Connect with decision makers from multiple functions at leading IO developers to form valuable business relationships

Position yourself within in discussion as the leading partner and showcase your expertise

Confirmed Partners

Expertise Partner

Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.

www.mitrabiotech.com

Expertise Partner

Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials.

www.appliedbiomath.com

Program Partner

Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies

www.personalis.com

Exhibitor

Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

www.immudex.com

GET INVOLVED

Denvor Oorloff
Partnerships Director
Tel: +44 (0)203 141 8748
Email: denvor.oorloff@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.ici-io.com/take-part/register

Tel: +1 617 455 4188

Email: info@hansonwade.com

1. Gain knowledge that will optimize your rationale when selecting Checkpoint Modulators and Combination Partners, to find the right combination sooner
2. Optimize your development process to advance your combination pipeline
3. Overcome the key roadblocks that prevent Checkpoint Modulator containing combinations from reaching the market

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Industry Pricing	Register by Friday, December 7	Standard Price
Conference + 1 Workshop	$3198 **(save $400)**	$3498 **(save $100)**
Conference Only	$2599 **(save $300)**	$2899
Workshops (Each)	$699	

Small Biotech Pricing	Register by Friday, December 7	Standard Price
Conference + 1 Workshop	$1898 **(save $400)**	$2198 **(save $100)**
Conference Only	$1599 **(save $300)**	$1899
Workshops (Each)	$399	

*T&Cs APPLY: small biotech pricing is subject to organizer approval, see website for more details.



VENUE

The Colonnade Hotel
120 Huntington Avenue, Boston,
MA 02116, Unites States

For further information or assistance, please visit
www.colonnadehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the four-teenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH